Research at DOE Sites: Savannah River Site Health Effect Subcommittee (SRS).

Times and Dates: 9 a.m.–5 p.m., January 11, 1996; 9 a.m.–12 noon, January 12, 1996.

Place: Hilton—The De Soto, 15 East Liberty Street, Savannah, Georgia 31401, telephone 912/232–9000, FAX 912/232–6018.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people.

Background: Under a Memorandum of Understanding (MOU) signed in December 1990 with DOE, the Department of Health and Human Services (HHS) has been given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS delegated program responsibility to CDC.

In addition, an MOU was signed in October 1990 and renewed in November 1992 between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or ''Superfund''). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

Purpose: This Subcommittee is charged with providing advice and recommendations to the Director, CDC and the Administrator, ATSDR, regarding community American Indian Tribes, and labor concerns pertaining to CDC's and ATSDR's public health activities and research at respective DOE sites. Activities shall focus on providing a forum for community, American Indian Tribal, and labor interaction and serve as a vehicle for community concern to be expressed as advice and recommendations to CDC and ATSDR.

Matters to be Discussed: This Subcommittee will listen to presentations from the Radiological Assessments Corporation, Medical University of South Carolina Cancer Registry, as well as updates on the Savannah River Site Phase II Dose Reconstruction Project findings and implications. Additional agenda items will include: the National Center for Environmental Health (NCEH) activities, the National Institute for Occupational Safety and Health and ATSDR presentations on the progress of current studies, and issues regarding the Committee selection process.

Agenda items are subject to change as priorities dictate.

Contact Persons for More Information: Paul G. Renard or Nadine Dickerson, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, (F–35), Atlanta, Georgia 30341–3724, telephone 770/488–7040, FAX 770/488–7044.

Dated: December 18, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 95–31152 Filed 12–21–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Grassroots Regulatory Partnership Meeting; Southwest Region; Importing Commodities

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of a public meeting.

SUMMARY: The Food and Drug Administration (FDA) (Office of Regulatory Affairs, Office of the Southwest Region, and Office of External Affairs) is announcing a free public meeting to discuss ways FDA could regulate imported commodities more efficiently, improve levels of communication with industries and individuals associated with the importation of FDA-regulated commodities, and provide improved levels of consumer protection in connection with imported commodities being shipped into the United States across the United States-Mexico border. This meeting is intended to identify and evaluate opportunities for implementing the President's initiative for a partnership approach between the agency and the people affected by the work of this agency.

DATES: The public meeting will be held on Wednesday, January 31, 1996, from 9 a.m. to 12 m.

ADDRESSES: The public meeting will be held at the Concourse Clarion Hotel, Oxford Room A and B, 6789 Boeing, El Paso, TX 79926.

FOR FURTHER INFORMATION CONTACT: Barbara A. Cain, Food and Drug Administration, 300 East Eight St., rm. B123, Austin, TX 78701, 512–482–5736, or Robert G. Rast, Food and Drug Administration, 9777 Via De La Amistad, rm. 128, San Diego, CA 92173, 619–661–3273.

SUPPLEMENTARY INFORMATION: There is no registration fee for this meeting. However, due to space limitations, early registration is recommended. This meeting is intended to assist importers, brokers, and others associated with a wide variety of products being shipped through the southwest and west coast (FDA Southwest and Pacific Regions).

Dated: December 15, 1995.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 95–31195 Filed 12–21–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0403]

Drug Export; SURGISCREEN® 0.8 Percent, Reagent Red Blood Cells

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ortho Diagnostic Systems, Inc., has filed an application requesting approval for the export of the human biological product SURGISCREEN® 0.8 percent, Reagent Red Blood Cells to Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Cathy E. Conn, Center for Biologics Evaluation and Research (HFM–610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its

review of the application. To meet this requirement, the agency is providing notice that Ortho Diagnostic Systems, Inc., 1001 U.S. Highway 202, Raritan, NJ 08869–0606, has filed an application requesting approval for the export of the human biological product SURGISCREEN® 0.8 percent, Reagent Red Blood Cells to Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom. The SURGISCREEN® 0.8 percent, Reagent Red Blood Cells, is an in vitro diagnostic test kit for the detection of unexpected blood group antibodies in test methods requiring a 0.8 percent red cell suspension in a low ionic strength diluent. The application was received and filed in the Center for Biologics Evaluation and Research on November 24, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by (*insert date 10 days after date of publication in the* Federal Register), and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: December 4, 1995.

James C. Simmons,

Director, Office of Compliance, Center for Biologics Evaluation and Research.

[FR Doc. 95–31153 Filed 12–21–95; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Community Planning and Development

[Docket No. FR–3778–N–67]

Federal Property Suitable as Facilities to Assist the Homeless

AGENCY: Office of the Assistant Secretary for Community Planning and Development, HUD.

ACTION: Notice.

SUMMARY: This Notice identifies unutilized,underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.

EFFECTIVE DATE: December 22, 1995.

FOR FURTHER INFORMATION CONTACT: Mark Johnston, Department of Housing and Urban Development, Room 7256, 451 Seventh Street SW, Washington, DC 20410; telephone (202) 708–1226; TDD number for the hearing-and speech-impaired (202) 708–2565, (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1–800–927–7588.

SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in *National Coalition for the Homeless* v. *Veterans Administration,* No. 88–2503–OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless. Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

Dated: December 15, 1995.

Jacquie M. Lawing,

Deputy Assistant Secretary for Economic Development.

[FR Doc. 95–31078 Filed 12–21–95; 8:45 am]

BILLING CODE 4210–29–M

DEPARTMENT OF THE INTERIOR

Bureau of Reclamation

[FES–95–40]

Cachuma Project Contract Renewal, Santa Barbara County, CA

AGENCY: Bureau of Reclamation, Interior.

ACTION: Notice of availability on the final environmental impact statement/ final environmental impact report.

SUMMARY: Pursuant to the National Environmental Policy Act (NEPA) of 1969 (as amended) and the California Environmental Quality Act (CEQA), the Bureau of Reclamation (Reclamation), the Cachuma Project Authority (Authority) and the Santa Barbara County Water Agency (Agency) have prepared a joint final environmental impact statement/final environmental impact report (FEIS/FEIR) for the Cachuma Project contract renewal. The proposed action of the lead agencies is the continuation of the member units' entitlement to water from the Cachuma Project by means of a renewed water service contract. The proposed action exercises the provisions of several Federal laws as applicable to Reclamation.

ADDRESSES: Copies of the FEIS/FEIR are available for public inspection and review at the following locations:

- Bureau of Reclamation, Program Analysis Office, Room 7456, 1849 C Street NW., Washington, DC 20240; telephone: (202) 208–4662.
- Bureau of Reclamation, Denver Office Library, Building 67, Room 167, Denver Federal Center, 6th and Kipling, Denver, CO 80225; telephone: (303) 236–6963.
- Bureau of Reclamation, Regional Director, Attention: MP–152, 2800 Cottage Way, Sacramento CA 95825–1898; telephone: (916) 979–5129.
- Bureau of Reclamation, South-Central California Area Office, Attention: SCC–412, 2666 N. Grove Industrial Drive, Suite 106, Fresno CA 93727–1551; telephone: (209) 487–5137.
- Cachuma Project Authority, 3301 Laurel Canyon Road, Santa Barbara CA 93105–2017; telephone: (805) 569–1391.
- Santa Barbara County Water Agency, 123 E. Anapamu Street, Santa Barbara CA 93101–2058; telephone: (805) 568–3542.

Libraries: Copies will also be available for inspection at public libraries located in Carpinteria, Montecito, Santa Barbara, Goleta, Solvang, Buellton, Vandenberg Village, Lompoc, and Santa Maria, California.

FOR FURTHER INFORMATION CONTACT: Mr. Robert May, Program Manager, SCC–412, Bureau of Reclamation, 2666 N. Grove Industrial Drive, Suite 106, Fresno CA 93727–1551; telephone: (209) 487–5137; or Mr. Chris Dahlstrom, Project Coordinator, Cachuma Project Authority, 3301 Laurel Canyon Road, Santa Barbara CA 93105–2017; telephone: (805) 569–1391; or Mr. Robert Almy, Santa Barbara County Water Agency, 123 E. Anapamu Street, Santa Barbara CA 93101–2058; telephone: (805) 568–3542.